Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

In this study, terbinafine reached high concentrations in stratum corneum and sebum after oral administration, with drug levels remaining above fungicidal concentrations for over three weeks.

This study found that topical niacinamide significantly improved the appearance of wrinkles, skin yellowing, and elasticity in aging facial skin over 12 weeks.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study reported that using human follicle stem cells isolated from hair bulge areas increased hair density by about 29% over baseline in patients with androgenetic alopecia, with significant improvements observed 23 weeks after the last treatment.

This retrospective study found that adipose-derived stem cell-conditioned media increased hair density and thickness in women with female pattern hair loss over 12 weeks, with no severe adverse effects reported.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

This study found that PRO 160/120 and Finasteride showed similar effectiveness in improving urinary symptoms and quality of life in patients with benign prostatic hyperplasia over 48 weeks.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

In this study, trilostane treatment led to complete hair re-growth in 85% of Pomeranians and all miniature poodles with alopecia X within 4 to 8 weeks.

In this case study, medical management with trilostane improved clinical signs and normalized serum chemistry in a dog diagnosed with adrenal-dependent hyperadrenocorticism over 80 weeks of treatment.

In this study, hair damaged by permanent dye showed signs of recovery over time, with near complete restoration to its original state after eight weeks.

In this study, a new cell-tissue technology using a patient's own skin to create a full-thickness skin autograft successfully treated a chronic wound larger than 200 cm², achieving complete functional skin coverage within 12 weeks and maintaining results at a 6-month follow-up.

The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.

In this study, a combined therapy of Cyclosporine A and ketoconazole resolved anal furunculosis in dogs within 10 weeks, but recurrences were noted in about 37% of cases.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This study found that eflornithine HCl 13.9% cream reduces unwanted facial hair growth in women, with effects seen in up to 60% of participants over 4-8 weeks, with mostly minor skin irritation reported.